A
mid widespread confusion over when the HIV prevention pill will go generic, a spokeswoman for Teva on Monday told STAT that the company has reached a confidential settlement controlling when it can enter the marketplace.
That spokeswoman, Elizabeth DeLuca, declined to say when Teva will launch its generic version of the drug currently sold by Gilead as Truvada, or how much it will charge.
Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!
SUBSCRIBE TODAYWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
About the Author
